Pre-made Priliximab benchmark antibody (Whole mAb, anti-CD4 therapeutic antibody, Anti-IMD79/OKT4D Antibody) for drug discovery and mechanism of action (MOA) research

Anti-CD4 therapeutic antibody (Pre-made Priliximab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Priliximab (cMT 412) is a human-mouse chimeric anti-CD4 monoclonal antibody. It has been tested on patients with Crohn's disease[1] and multiple sclerosis[2][3] but has not yet received U.S. Food and Drug Administration licensing. The patent belongs to the biotechnology company Centocor.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-965-1mg	1mg	3090
GMP-Bios-INN-965-10mg	10mg	Inquiry
GMP-Bios-INN-965-100mg	100mg	Inquiry
GMP-Bios-INN-965-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Priliximab Biosimilar, Whole Mab, Anti-Cd4 Antibody: Anti-IMD79/OKT4D therapeutic antibody
INN Name	Priliximab
Target	CD4
Format	Whole mAb
Derivation	Chimeric
Species Reactivity	human
CH1 Isotype	IgG1 - kappa
VD LC	IgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Centocor Inc. (Horsham PA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0